Comparative expression study of the endo-G protein coupled receptor (GPCR) repertoire in human glioblastoma cancer stem-like cells, U87-MG cells and non malignant cells of neural origin unveils new potential therapeutic targets

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Fève, Marie ^a   Saliou, Jean Michel ^a   Zeniou, Maria ^a   Lennon, Sarah ^a   Carapito, Christine ^a   Dong, Jihu ^a   Van Dorsselaer, Alain ^a   Junier, Marie Pierre ^b   Chneiweiss, Hervé ^b   Cianférani, Sarah ^a   Haiech, Jacques ^a   Kilhoffer, Marie Claude ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b and Centre National de la Recherche Scientifique Unité Mixte de Recherche 8246   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADRENOMEDULLIN; ANANDAMIDE; CADHERIN; COLLAGEN TYPE 3; COMPLEMENT COMPONENT C1Q; DECAY ACCELERATING FACTOR; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; ORPHAN NUCLEAR RECEPTOR; SPHINGOSINE 1 PHOSPHATE; STROMAL CELL DERIVED FACTOR 1; WNT PROTEIN;

ARTICLE; ASTROCYTE; CANCER STEM CELL; CELL FUNCTION; CELL SPECIFICITY; CELL TYPE; COMPARATIVE STUDY; DESCRIPTIVE RESEARCH; DOWN REGULATION; EMBRYO; FETUS; GENE CLUSTER; GLIOBLASTOMA; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MASS SPECTROMETRY; NEURAL STEM CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEOMICS; CELL DIFFERENTIATION; CYTOLOGY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PLOIDY; TUMOR CELL LINE;

ASTROCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; FETUS; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PLOIDIES; PROTEOMICS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84899752025     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091519     Document Type: Article

References (180)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 14 Suppl 5: v1-49.
2. Schechter CB (1999) Re: Brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91: 2050-2051.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
4. Holdhoff M, Grossman SA (2011) Controversies in the adjuvant therapy of high-grade gliomas. Oncologist 16: 351-358.
5. Yin AA, Cheng JX, Zhang X, Liu BL (2013) The treatment of glioblastomas: a systematic update on clinical Phase III trials. Crit Rev Oncol Hematol 87: 265-282.
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
7. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737. (Pubitemid 27298715)
8. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111. (Pubitemid 33041634)
9. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, et al. (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100: 15178-15183. (Pubitemid 37518036)
10. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828. (Pubitemid 37187480)
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988. (Pubitemid 36418143)
12. Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284. (Pubitemid 46706514)
13. O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110. (Pubitemid 46067310)
14. Schatton T, Frank MH (2008) Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 21: 39-55. (Pubitemid 351421465)
15. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al. (2008) Identification of cells initiating human melanomas. Nature 451: 345-349.
16. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323. (Pubitemid 47355323)
17. Chen J, Li Y, Yu TS, McKay RM, Burns DK, et al. (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature.
18. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C (2012) Defining the mode of tumour growth by clonal analysis. Nature.
19. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, et al. (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337: 730-735.
20. Frank NY, Schatton T, Frank MH (2010) The therapeutic promise of the cancer stem cell concept. J Clin Invest 120: 41-50.
21. Alison MR, Lin WR, Lim SM, Nicholson LJ (2012) Cancer stem cells: in the line of fire. Cancer Treat Rev 38: 589-598.
22. Sharkis SJ, Jones RJ, Civin C, Jang YY (2012) Pluripotent stem cell-based cancer therapy: promise and challenges. Sci Transl Med 4: 127ps129.
23. Lee C, Dunn SE, Yip S (2012) Stem cells in brain tumour development and therapy- two-sides of the same coin. Can J Neurol Sci 39: 145-156.
24. Nduom EK, Hadjipanayis CG, Van Meir EG (2012) Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment. Cancer J 18: 100-106.
25. Malik B, Nie D (2012) Cancer stem cells and resistance to chemo and radio therapy. Front Biosci (Elite Ed) 4: 2142-2149.
26. Persano L, Rampazzo E, Basso G, Viola G (2013) Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. Biochem Pharmacol 85: 612-622.
27. Patru C, Romao L, Varlet P, Coulombel L, Raponi E, et al. (2010) CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer 10: 66.
28. Drews J (2000) Drug discovery: a historical perspective. Science 287: 1960-1964.
29. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1: 727-730. (Pubitemid 37361545)
30. Jacoby E, Bouhelal R, Gerspacher M, Seuwen K (2006) The 7 TM G-protein-coupled receptor target family. ChemMedChem 1: 761-782.
31. Garland SL (2013) Are GPCRs Still a Source of New Targets? J Biomol Screen.
32. Lappano R, Maggiolini M (2011) G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 10: 47-60.
33. Herr DR (2012) Potential use of G protein-coupled receptor-blocking monoclonal antibodies as therapeutic agents for cancers. Int Rev Cell Mol Biol 297: 45-81.
34. Dorsam RT, Gutkind JS (2007) G-protein-coupled receptors and cancer. Nat Rev Cancer 7: 79-94. (Pubitemid 46164746)
35. Audigier Y, Picault FX, Chaves-Almagro C, Masri B (2013) G Protein-Coupled Receptors in cancer: biochemical interactions and drug design. Prog Mol Biol Transl Sci 115: 143-173.
36. Feigin ME (2013) Harnessing the genome for characterization of GPCRs in cancer pathogenesis. FEBS J.
37. Axelson M, Liu K, Jiang X, He K, Wang J, et al. (2013) U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res 19: 2289-2293.
38. Webb DR, Handel TM, Kretz-Rommel A, Stevens RC (2013) Opportunities for functional selectivity in GPCR antibodies. Biochem Pharmacol 85: 147-152.
39. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
40. Valente V, Teixeira SA, Neder L, Okamoto OK, Oba-Shinjo SM, et al. (2009) Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. BMC Mol Biol 10: 17.
41. Mackrill JJ (2004) Generation, use, and validation of receptor-selective antibodies. Methods Mol Biol 259: 47-65.
42. Jensen BC, Swigart PM, Simpson PC (2009) Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch Pharmacol 379: 409-412.
43. Bodei S, Arrighi N, Spano P, Sigala S (2009) Should we be cautious on the use of commercially available antibodies to dopamine receptors? Naunyn Schmiedebergs Arch Pharmacol 379: 413-415.
44. Hamdani N, van der Velden J (2009) Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379: 403-407.
45. Pradidarcheep W, Stallen J, Labruyere WT, Dabhoiwala NF, Michel MC, et al. (2009) Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379: 397-402.
46. Beermann S, Seifert R, Neumann D (2012) Commercially available antibodies against human and murine histamine H(4)-receptor lack specificity. Naunyn Schmiedebergs Arch Pharmacol 385: 125-135.
47. Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, et al. (1997) CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57: 1798-1806. (Pubitemid 27199676)
48. Chidambaram A, Fillmore HL, Van Meter TE, Dumur CI, Broaddus WC (2012) Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness. J Neurosurg 116: 843-853.
49. Ward Y, Lake R, Yin JJ, Heger CD, Raffeld M, et al. (2011) LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res 71: 7301-7311.
50. Ward Y, Lake R, Martin PL, Killian K, Salerno P, et al. (2013) CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. Oncogene 32: 2726-2738.
51. Safaee M, Clark AJ, Oh MC, Ivan ME, Bloch O, et al. (2013) Overexpression of CD97 confers an invasive phenotype in glioblastoma cells and is associated with decreased survival of glioblastoma patients. PLoS One 8: e62765.
52. Liu D, Trojanowicz B, Radestock Y, Fu T, Hammje K, et al. (2010) Role of CD97 isoforms in gastric carcinoma. Int J Oncol 36: 1401-1408.
53. Shashidhar S, Lorente G, Nagavarapu U, Nelson A, Kuo J, et al. (2005) GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene 24: 1673-1682. (Pubitemid 40461124)
54. Xu L, Begum S, Hearn JD, Hynes RO (2006) GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci U S A 103: 9023-9028. (Pubitemid 43902526)
55. Xu L, Begum S, Barry M, Crowley D, Yang L, et al. (2010) GPR56 plays varying roles in endogenous cancer progression. Clin Exp Metastasis 27: 241-249.
56. Yang L, Chen G, Mohanty S, Scott G, Fazal F, et al. (2011) GPR56 Regulates VEGF production and angiogenesis during melanoma progression. Cancer Res 71: 5558-5568.
57. Luo R, Jeong SJ, Jin Z, Strokes N, Li S, et al. (2011) G protein-coupled receptor 56 and collagen III, a receptor-ligand pair, regulates cortical development and lamination. Proc Natl Acad Sci U S A 108: 12925-12930.
58. Terskikh AV, Easterday MC, Li L, Hood L, Kornblum HI, et al. (2001) From hematopoiesis to neuropoiesis: evidence of overlapping genetic programs. Proc Natl Acad Sci U S A 98: 7934-7939. (Pubitemid 32642665)
59. Bai Y, Du L, Shen L, Zhang Y, Zhang L (2009) GPR56 is highly expressed in neural stem cells but downregulated during differentiation. Neuroreport 20: 918-922.
60. Cork SM, Van Meir EG (2011) Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development. J Mol Med (Berl) 89: 743-752.
61. Kaur B, Brat DJ, Calkins CC, Van Meir EG (2003) Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol 162: 19-27. (Pubitemid 36041986)
62. Kang X, Xiao X, Harata M, Bai Y, Nakazaki Y, et al. (2006) Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas. Cancer Gene Ther 13: 385-392.
63. Cork SM, Kaur B, Devi NS, Cooper L, Saltz JH, et al. (2012) A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1. Oncogene.
64. Okajima D, Kudo G, Yokota H (2010) Brain-specific angiogenesis inhibitor 2 (BAI2) may be activated by proteolytic processing. J Recept Signal Transduct Res 30: 143-153.
65. Kee HJ, Ahn KY, Choi KC, Won Song J, Heo T, et al. (2004) Expression of brain-specific angiogenesis inhibitor 3 (BAI3) in normal brain and implications for BAI3 in ischemia-induced brain angiogenesis and malignant glioma. FEBS Lett 569: 307-316. (Pubitemid 38844637)
66. Garcia-Lopez MT, Gutierrez-Rodriguez M, Herranz R (2010) Thrombin-activated receptors: promising targets for cancer therapy? Curr Med Chem 17: 109-128.
67. Elste AP, Petersen I (2010) Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer. J Mol Histol 41: 89-99.
68. Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J (2008) Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene 27: 4434-4445.
69. Gessler F, Voss V, Dutzmann S, Seifert V, Gerlach R, et al. (2010) Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells. Neuroscience 165: 1312-1322.
70. Dutzmann S, Gessler F, Harter PN, Gerlach R, Mittelbronn M, et al. (2010) The pro-migratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas. Cell Adh Migr 4: 515-522.
71. Magnus N, Garnier D, Rak J (2010) Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood 116: 815-818.
72. Zigler M, Kamiya T, Brantley EC, Villares GJ, Bar-Eli M (2011) PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. Cancer Res 71: 6561-6566.
73. Robbins MJ, Michalovich D, Hill J, Calver AR, Medhurst AD, et al. (2000) Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C). Genomics 67: 8-18. (Pubitemid 30471116)
74. Brauner-Osborne H, Krogsgaard-Larsen P (2000) Sequence and expression pattern of a novel human orphan G-protein-coupled receptor, GPRC5B, a family C receptor with a short amino-terminal domain. Genomics 65: 121-128. (Pubitemid 30314419)
75. Harada Y, Yokota C, Habas R, Slusarski DC, He X (2007) Retinoic acid-inducible G protein-coupled receptors bind to frizzled receptors and may activate non-canonical Wnt signaling. Biochem Biophys Res Commun 358: 968-975. (Pubitemid 46828983)
76. Cool BH, Chan GC, Lee L, Oshima J, Martin GM, et al. (2010) A flanking gene problem leads to the discovery of a Gprc5b splice variant predominantly expressed in C57Bl/6J mouse brain and in maturing neurons. PLoS One 5: e10351.
77. Usui T, Shima Y, Shimada Y, Hirano S, Burgess RW, et al. (1999) Flamingo, a seven-pass transmembrane cadherin, regulates planar cell polarity under the control of Frizzled. Cell 98: 585-595. (Pubitemid 29418950)
78. Boutin C, Goffinet AM, Tissir F (2012) Celsr1-3 cadherins in PCP and brain development. Curr Top Dev Biol 101: 161-183.
79. Tissir F, Goffinet AM (2006) Expression of planar cell polarity genes during development of the mouse CNS. Eur J Neurosci 23: 597-607.
80. Tissir F, Qu Y, Montcouquiol M, Zhou L, Komatsu K, et al. (2010) Lack of cadherins Celsr2 and Celsr3 impairs ependymal ciliogenesis, leading to fatal hydrocephalus. Nat Neurosci 13: 700-707.
81. Sugimura R, He XC, Venkatraman A, Arai F, Box A, et al. (2012) Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche. Cell 150: 351-365.
82. Wada H, Tanaka H, Nakayama S, Iwasaki M, Okamoto H (2006) Frizzled3a and Celsr2 function in the neuroepithelium to regulate migration of facial motor neurons in the developing zebrafish hindbrain. Development 133: 4749-4759. (Pubitemid 46063087)
83. Katoh M (2005) WNT/PCP signaling pathway and human cancer (review). Oncol Rep 14: 1583-1588.
84. Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S, et al. (2005) Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer Res 11: 4357-4364. (Pubitemid 40825624)
85. Terasaki M, Sugita Y, Arakawa F, Okada Y, Ohshima K, et al. (2011) CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target. Brain Tumor Pathol 28: 89-97.
86. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, et al. (2013) A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49: 219-230.
87. Ehtesham M, Mapara KY, Stevenson CB, Thompson RC (2009) CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett 274: 305-312.
88. Schulte A, Gunther HS, Phillips HS, Kemming D, Martens T, et al. (2011) A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target. Glia 59: 590-602.
89. Fareh M, Turchi L, Virolle V, Debruyne D, Almairac F, et al. (2012) The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ 19: 232-244.
90. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, et al. (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153: 139-152.
91. Rao S, Sengupta R, Choe EJ, Woerner BM, Jackson E, et al. (2012) CXCL12 mediates trophic interactions between endothelial and tumor cells in glioblastoma. PLoS One 7: e33005.
92. Li M, Chang CJ, Lathia JD, Wang L, Pacenta HL, et al. (2011) Chemokine receptor CXCR4 signaling modulates the growth factor-induced cell cycle of self-renewing and multipotent neural progenitor cells. Glia 59: 108-118.
93. Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin MM, et al. (1998) GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 396: 674-679. (Pubitemid 29003945)
94. White JH, Wise A, Main MJ, Green A, Fraser NJ, et al. (1998) Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 396: 679-682. (Pubitemid 29003946)
95. Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, et al. (1998) GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 396: 683-687. (Pubitemid 29003947)
96. Billinton A, Ige AO, Wise A, White JH, Disney GH, et al. (2000) GABA(B) receptor heterodimer-component localisation in human brain. Brain Res Mol Brain Res 77: 111-124. (Pubitemid 30256197)
97. Villemure JF, Adam L, Bevan NJ, Gearing K, Chenier S, et al. (2005) Subcellular distribution of GABA(B) receptor homo- and hetero-dimers. Biochem J 388: 47-55. (Pubitemid 40732931)
98. Maurel D, Comps-Agrar L, Brock C, Rives ML, Bourrier E, et al. (2008) Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat Methods 5: 561-567. (Pubitemid 351761765)
99. Chang W, Tu C, Cheng Z, Rodriguez L, Chen TH, et al. (2007) Complex formation with the Type B gamma-aminobutyric acid receptor affects the expression and signal transduction of the extracellular calcium-sensing receptor. Studies with HEK-293 cells and neurons. J Biol Chem 282: 25030-25040. (Pubitemid 47347560)
100. Boyer SB, Clancy SM, Terunuma M, Revilla-Sanchez R, Thomas SM, et al. (2009) Direct interaction of GABAB receptors with M2 muscarinic receptors enhances muscarinic signaling. J Neurosci 29: 15796-15809.
101. Fernando RN, Eleuteri B, Abdelhady S, Nussenzweig A, Andang M, et al. (2011) Cell cycle restriction by histone H2AX limits proliferation of adult neural stem cells. Proc Natl Acad Sci U S A 108: 5837-5842.
102. Kriegstein AR (2005) GABA puts the brake on stem cells. Nat Neurosci 8: 1132-1133.
103. Fukui M, Nakamichi N, Yoneyama M, Ozawa S, Fujimori S, et al. (2008) Modulation of cellular proliferation and differentiation through GABA(B) receptors expressed by undifferentiated neural progenitor cells isolated from fetal mouse brain. J Cell Physiol 216: 507-519. (Pubitemid 351898479)
104. Oka M, Wada M, Wu Q, Yamamoto A, Fujita T (2006) Functional expression of metabotropic GABAB receptors in primary cultures of astrocytes from rat cerebral cortex. Biochem Biophys Res Commun 341: 874-881. (Pubitemid 43177570)
105. Mizuta K, Osawa Y, Mizuta F, Xu D, Emala CW (2008) Functional expression of GABAB receptors in airway epithelium. Am J Respir Cell Mol Biol 39: 296-304.
106. Tamura S, Watanabe M, Kanbara K, Yanagawa T, Watanabe K, et al. (2009) Expression and distribution of GABAergic system in rat knee joint synovial membrane. Histol Histopathol 24: 1009-1019.
107. Zhou Z, Sun H, Li X, Li Y, Zhao S, et al. (2010) A local GABAergic system is functionally expressed in human fallopian tube. Biochem Biophys Res Commun 398: 237-241.
108. Jiang X, Su L, Zhang Q, He C, Zhang Z, et al. (2012) GABAB Receptor Complex as a Potential Target for Tumor Therapy. J Histochem Cytochem 60: 269-279.
109. Roberts SS, Mendonca-Torres MC, Jensen K, Francis GL, Vasko V (2009) GABA receptor expression in benign and malignant thyroid tumors. Pathol Oncol Res 15: 645-650.
110. Wang T, Huang W, Chen F (2008) Baclofen, a GABAB receptor agonist, inhibits human hepatocellular carcinoma cell growth in vitro and in vivo. Life Sci 82: 536-541.
111. Tatsuta M, Iishi H, Baba M, Taniguchi H (1992) Attenuation by the GABA receptor agonist baclofen of experimental carcinogenesis in rat colon by azoxymethane. Oncology 49: 241-245.
112. Hannan S, Wilkins ME, Dehghani-Tafti E, Thomas P, Baddeley SM, et al. (2011) GABAB receptor internalisation is regulated by the R2 subunit. J Biol Chem.
113. Carmon KS, Gong X, Lin Q, Thomas A, Liu Q (2011) R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A 108: 11452-11457.
114. de Lau W, Barker N, Low TY, Koo BK, Li VS, et al. (2011) Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476: 293-297.
115. Birchmeier W (2011) Stem cells: Orphan receptors find a home. Nature 476: 287-288.
116. Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, et al. (2011) Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469: 415-418.
117. Snippert HJ, Clevers H (2011) Tracking adult stem cells. EMBO Rep 12: 113-122.
118. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007. (Pubitemid 350014593)
119. Mustata RC, Van Loy T, Lefort A, Libert F, Strollo S, et al. (2011) Lgr4 is required for Paneth cell differentiation and maintenance of intestinal stem cells ex vivo. EMBO Rep 12: 558-564.
120. Kato S, Matsubara M, Matsuo T, Mohri Y, Kazama I, et al. (2006) Leucine-rich repeat-containing G protein-coupled receptor-4 (LGR4, Gpr48) is essential for renal development in mice. Nephron Exp Nephrol 104: e63-75. (Pubitemid 44450473)
121. Oyama K, Mohri Y, Sone M, Nawa A, Nishimori K (2011) Conditional knockout of Lgr4 leads to impaired ductal elongation and branching morphogenesis in mouse mammary glands. Sex Dev 5: 205-212.
122. Wang Z, Jin C, Li H, Li C, Hou Q, et al. (2010) GPR48-Induced keratinocyte proliferation occurs through HB-EGF mediated EGFR transactivation. FEBS Lett 584: 4057-4062.
123. Gao Y, Kitagawa K, Hiramatsu Y, Kikuchi H, Isobe T, et al. (2006) Upregulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis. Cancer Res 66: 11623-11631. (Pubitemid 46094173)
124. Gao Y, Shan ZY, Wang H, Zhang HM, Teng WP (2009) Inhibitory effect of shRNA targeting GPR48 on invasion and metastasis of human cervical carcinoma cell line HeLa. Ai Zheng 28: 104-107.
125. Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58: 1017-1030.
126. Zhuang M, Yang Y, Cao F, Lu M, Wang X, et al. (2012) Associations of variants of CNR1 with obesity and obesity-related traits in Chinese women. Gene 495: 194-198.
127. Verde Z, Santiago C, Rodriguez Gonzalez-Moro JM, de Lucas Ramos P, Lopez Martin S, et al. (2011) 'Smoking genes': a genetic association study. PLoS One 6: e26668.
128. Smith SB, Maixner DW, Fillingim RB, Slade G, Gracely RH, et al. (2012) Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia. Arthritis Rheum 64: 584-593.
129. Carracedo A, Lorente M, Egia A, Blazquez C, Garcia S, et al. (2006) The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9: 301-312.
130. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, et al. (2009) Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 119: 1359-1372.
131. Cudaback E, Marrs W, Moeller T, Stella N (2010) The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS One 5: e8702.
132. Aguado T, Carracedo A, Julien B, Velasco G, Milman G, et al. (2007) Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem 282: 6854-6862. (Pubitemid 47100911)
133. Wu X, Han L, Zhang X, Li L, Jiang C, et al. (2012) Alteration of endocannabinoid system in human gliomas. J Neurochem 120: 842-849.
134. Held-Feindt J, Dorner L, Sahan G, Mehdorn HM, Mentlein R (2006) Cannabinoid receptors in human astroglial tumors. J Neurochem 98: 886-893. (Pubitemid 44051288)
135. Schley M, Stander S, Kerner J, Vajkoczy P, Schupfer G, et al. (2009) Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull 79: 333-337.
136. De Jesus ML, Hostalot C, Garibi JM, Salles J, Meana JJ, et al. (2010) Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. Neurochem Int 56: 829-833.
137. Marshall AD, Lagutina I, Grosveld GC (2011) PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. Cancer Res 71: 7471-7480.
138. Kenessey I, Banki B, Mark A, Varga N, Tovari J, et al. (2012) Revisiting CB1 Receptor as Drug Target in Human Melanoma. Pathol Oncol Res.
139. Proto MC, Gazzerro P, Di Croce L, Santoro A, Malfitano AM, et al. (2012) Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J Cell Physiol 227: 250-258.
140. Silva JP, Ushkaryov YA (2010) The latrophilins, "split- personality" receptors. Adv Exp Med Biol 706: 59-75.
141. Matsushita H, Lelianova VG, Ushkaryov YA (1999) The latrophilin family: multiply spliced G protein-coupled receptors with differential tissue distribution. FEBS Lett 443: 348-352. (Pubitemid 29080824)
142. Ichtchenko K, Bittner MA, Krasnoperov V, Little AR, Chepurny O, et al. (1999) A novel ubiquitously expressed alpha-latrotoxin receptor is a member of the CIRL family of G-protein-coupled receptors. J Biol Chem 274: 5491-5498. (Pubitemid 29109196)
143. Doyle SE, Scholz MJ, Greer KA, Hubbard AD, Darnell DK, et al. (2006) Latrophilin-2 is a novel component of the epithelial-mesenchymal transition within the atrioventricular canal of the embryonic chicken heart. Dev Dyn 235: 3213-3221. (Pubitemid 44888187)
144. Boucard AA, Ko J, Sudhof TC (2012) High Affinity Neurexin Binding to Cell Adhesion G-protein-coupled Receptor CIRL1/Latrophilin-1 Produces an Intercellular Adhesion Complex. J Biol Chem 287: 9399-9413.
145. Silva JP, Lelianova VG, Ermolyuk YS, Vysokov N, Hitchen PG, et al. (2011) Latrophilin 1 and its endogenous ligand Lasso/teneurin-2 form a high-affinity transsynaptic receptor pair with signaling capabilities. Proc Natl Acad Sci U S A 108: 12113-12118.
146. O'Sullivan ML, de Wit J, Savas JN, Comoletti D, Otto-Hitt S, et al. (2012) FLRT Proteins Are Endogenous Latrophilin Ligands and Regulate Excitatory Synapse Development. Neuron 73: 903-910.
147. White GR, Varley JM, Heighway J (1998) Isolation and characterization of a human homologue of the latrophilin gene from a region of 1p31.1 implicated in breast cancer. Oncogene 17: 3513-3519. (Pubitemid 29050687)
148. Eng L, Ibrahim-zada I, Jarjanazi H, Savas S, Meschian M, et al. (2011) Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines. BMC Med Genomics 4: 18.
149. Yang G, Quan Y, Wang W, Fu Q, Wu J, et al. (2012) Dynamic equilibrium between cancer stem cells and non-stem cancer cells in human SW620 and MCF-7 cancer cell populations. Br J Cancer.
150. Garritano S, Inga A, Gemignani F, Landi S (2013) More targets, more pathways and more clues for mutant p53. Oncogenesis 2: e54.
151. Del Valle J, Gantz I (1997) Novel insights into histamine H2 receptor biology. Am J Physiol 273: G987-996. (Pubitemid 27508259)
152. Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, et al. (1997) International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 49: 253-278. (Pubitemid 27414915)
153. Medina VA, Rivera ES (2010) Histamine receptors and cancer pharmacology. Br J Pharmacol 161: 755-767.
154. Kubecova M, Kolostova K, Pinterova D, Kacprzak G, Bobek V (2011) Cimetidine: an anticancer drug? Eur J Pharm Sci 42: 439-444.
155. Zheng Y, Xu M, Li X, Jia J, Fan K, et al. (2013) Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol 54: 74-83.
156. Lisy K (2013) Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Clin J Oncol Nurs 17: 211-212.
157. Deva S, Jameson M (2012) Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database Syst Rev 8: CD007814.
158. Cricco G, Martin G, Medina V, Nunez M, Mohamad N, et al. (2006) Histamine inhibits cell proliferation and modulates the expression of Bcl-2 family proteins via the H2 receptor in human pancreatic cancer cells. Anticancer Res 26: 4443-4450. (Pubitemid 46031520)
159. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, et al. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393: 333-339. (Pubitemid 28269699)
160. Oehler MK, Norbury C, Hague S, Rees MC, Bicknell R (2001) Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene 20: 2937-2945. (Pubitemid 33027761)
161. Martinez A, Vos M, Guedez L, Kaur G, Chen Z, et al. (2002) The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst 94: 1226-1237. (Pubitemid 34993873)
162. Metellus P, Voutsinos-Porche B, Nanni-Metellus I, Colin C, Fina F, et al. (2011) Adrenomedullin expression and regulation in human glioblastoma, cultured human glioblastoma cell lines and pilocytic astrocytoma. Eur J Cancer 47: 1727-1735.
163. Kaafarani I, Fernandez-Sauze S, Berenguer C, Chinot O, Delfino C, et al. (2009) Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J 23: 3424-3435.
164. Pyne NJ, Tonelli F, Lim KG, Long JS, Edwards J, et al. (2012) Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans 40: 94-100.
165. Huang X, Wang Y, Nan X, He S, Xu X, et al. (2013) The role of the orphan G protein-coupled receptor 37 (GPR37) in multiple myeloma cells. Leuk Res.
166. Bhola NE, Grandis JR (2008) Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 13: 1857-1865. (Pubitemid 351599738)
167. Daub H, Weiss FU, Wallasch C, Ullrich A (1996) Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379: 557-560. (Pubitemid 26049585)
168. Delcourt N, Bockaert J, Marin P (2007) GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol Sci 28: 602-607. (Pubitemid 350166573)
169. Lappano R, De Marco P, De Francesco EM, Chimento A, Pezzi V, et al. (2013) Cross-talk between GPER and growth factor signaling. J Steroid Biochem Mol Biol.
170. Yu FX, Guan KL (2013) The Hippo pathway: regulators and regulations. Genes Dev 27: 355-371.
171. O'Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, et al. (2013) The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer 13: 412-424.
172. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869-873.
173. Wootten D, Christopoulos A, Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12: 630-644.
174. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. (Pubitemid 47103521)
175. Varlet P, Soni D, Miquel C, Roux FX, Meder JF, et al. (2004) New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases. Neurosurgery 55: 1377-1391: discussion 1391-1372.
176. Galan-Moya EM, Le Guelte A, Lima Fernandes E, Thirant C, Dwyer J, et al. (2011) Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Rep 12: 470-476.
177. Thirant C, Bessette B, Varlet P, Puget S, Cadusseau J, et al. (2011) Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors. PLoS One 6: e16375.
178. Miguet L, Bechade G, Fornecker L, Zink E, Felden C, et al. (2009) Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis. J Proteome Res 8: 3346-3354.
179. Geer LY, Markey SP, Kowalak JA, Wagner L, Xu M, et al. (2004) Open mass spectrometry search algorithm. J Proteome Res 3: 958-964. (Pubitemid 39425651)
180. Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 98: 31-36. (Pubitemid 32095858)